Harnessing oncolytic virus-mediated immunity
Oncolytic viruses (OVs) have emerged as a promising anticancer treatment. OVs selectively infect, replicate in, and kill tumor cells. Oncolytic viral therapy occurs in two phases: an initial phase where the virus mediates direct oncolysis of tumor cells, and a second phase where an induced post-onco...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Online |
| Jazyk: | angličtina |
| Vydáno: |
Frontiers Media SA
2021
|
| Témata: | |
| On-line přístup: | 18596 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
Podobné jednotky: Harnessing oncolytic virus-mediated immunity
- Oncolytic Viruses - Genetically Engineering the Future of Cancer Therapy
- Molecular Therapy: Oncolytics
- Oncolytic Virus Immunotherapy
- Evolution of NK-mediated target recognition under the pressure of physiologic or pathologic stimuli
- NK Cell Subsets in Health and Disease: New Developments
- Immunogenic Cell Death in Cancer: From Benchside Research to Bedside